MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Prostate
Janux Therapeutics, Inc (NASDAQ: JANX)*
Organization & Developments: Janux Therapeutics
Parents
Janux Therapeutics, Inc (NASDAQ: JANX)*
Children
*Biopharmaceutical company focused on developing a pipeline of immunotherapies by applying its technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to treat patients suffering from cancer.
2023: Janux Therapeutics: Precision Immunotherapy, But Overpriced For Such An Early Stage_ seekingalpha
2024: Evaluating Janux Therapeutics: Insights From 6 Financial Analysts
2024: Janux impresses Wall Street with new prostate cancer drug results
2024: Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
2024: Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation
2024: Janux Therapeutics: Yes There's New Data; No It's Not A Buy Here
2024: Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024
2024: Janux's shares jump 130% as analysts see blockbuster potential in phase 1 T-cell engager data
2024: Trial Data Triggers Massive Rally In Janux Therapeutics
2025: Janux T-cell engager data sink stock, but analysts still see best-in-class potential
2025: Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data
Jumps
Finance & Acquisitions: Janux Therapeutics
Key People: Janux Therapeutics